111
Participants
Start Date
October 31, 2009
Primary Completion Date
December 31, 2013
Study Completion Date
March 31, 2014
temozolomide
TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
temsirolimus
CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau, Nantes-Saint Herblain
UZ Leuven, Leuven
Ospedale Regionale Bellinzona e Valli, Bellinzona
Clatterbridge Cancer Centre NHS Foundation Trust, Bebington
Western General Hospital, Edinburgh
CHU Pitie-Salpetriere AP-HP, Paris
Universitaetsklinikum Freiburg, Freiburg im Breisgau
Universitatsklinikum Heidelberg, Heidelberg
Ospedale Bellaria, Bologna
Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam
Medisch Centrum Haaglanden - Westeinde, The Hague
ICO Badalona - Hospital Germans Trias i Pujol, Badalona
UniversitaetsSpital Zuerich, Zurich
Collaborators (1)
Pfizer
INDUSTRY
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK